Intrexon Corporation (NYSE:XON)‘s stock had its “buy” rating reissued by analysts at Griffin Securities in a note issued to investors on Friday. They currently have a $55.00 price objective on the biotechnology company’s stock. Griffin Securities’ target price would suggest a potential upside of 169.74% from the stock’s previous close.

Several other research firms have also issued reports on XON. BidaskClub raised shares of Intrexon Corporation from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Zacks Investment Research lowered shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Northland Securities set a $30.00 target price on shares of Intrexon Corporation and gave the stock a “buy” rating in a report on Monday, August 7th. Finally, JMP Securities reissued an “outperform” rating and issued a $42.00 target price on shares of Intrexon Corporation in a report on Thursday. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $43.80.

Intrexon Corporation (NYSE XON) opened at 20.39 on Friday. The company’s market capitalization is $2.46 billion. The stock has a 50 day moving average of $19.03 and a 200-day moving average of $21.10. Intrexon Corporation has a 52-week low of $17.03 and a 52-week high of $32.90.

Intrexon Corporation (NYSE:XON) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The company had revenue of $54.40 million during the quarter, compared to analyst estimates of $57.17 million. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.42) EPS. On average, equities research analysts anticipate that Intrexon Corporation will post ($0.87) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/06/griffin-securities-reiterates-buy-rating-for-intrexon-corporation-xon.html.

In other news, CEO Randal J. Kirk bought 132,625 shares of Intrexon Corporation stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average cost of $18.85 per share, with a total value of $2,499,981.25. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert B. Shapiro bought 2,850 shares of Intrexon Corporation stock in a transaction that occurred on Tuesday, August 22nd. The stock was purchased at an average cost of $17.50 per share, with a total value of $49,875.00. Following the completion of the acquisition, the director now directly owns 43,157 shares in the company, valued at approximately $755,247.50. The disclosure for this purchase can be found here. Insiders purchased a total of 144,569 shares of company stock valued at $2,719,429 over the last three months. 55.10% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd purchased a new stake in Intrexon Corporation during the 2nd quarter valued at approximately $262,000. Raymond James Financial Services Advisors Inc. grew its holdings in Intrexon Corporation by 4.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 59,146 shares of the biotechnology company’s stock valued at $1,425,000 after buying an additional 2,468 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Intrexon Corporation by 2,031.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 4,937 shares in the last quarter. BlueCrest Capital Management Ltd purchased a new stake in Intrexon Corporation during the 2nd quarter valued at approximately $438,000. Finally, Gotham Asset Management LLC purchased a new stake in Intrexon Corporation during the 2nd quarter valued at approximately $338,000. 82.11% of the stock is owned by institutional investors.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.